BAY94-9027: Phase II/III started

Bayer began the open-label, international Phase II/III PROTECT VIII Kids trial to evaluate prophylaxis (given at least once weekly) or on-demand treatment of 25-60 IU/kg IV BAY94-9027 for about 6 mont...